AIN457
( DrugBank: - / KEGG DRUG: - )
8 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 13 | 多発性硬化症／視神経脊髄炎 | 16 |
| 37 | 膿疱性乾癬（汎発型） | 9 |
| 41 | 巨細胞性動脈炎 | 11 |
| 46 | 悪性関節リウマチ | 48 |
13. 多発性硬化症／視神経脊髄炎
臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238
Showing 1 to 10 of 16 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2012-004019-29-PL (EUCTR) | 07/10/201320131007 | 02/09/201320130902 | Efficacy and safety of AIN457 to treat patients with relapsing multiple sclerosis | A Phase II, multicenter, randomized, double-blind, parallel group, placebo-controlled, adaptive dose-ranging study to evaluate the efficacy and safety of AIN457 in patients with relapsing multiple sclerosis A Phase II, multicenter, randomized, double-blind, parallel group, placebo-controlled, adaptive dose ... | Relapsing multiple sclerosis MedDRA version: 14.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Relapsing multiple sclerosis MedDRA version: 14.1;Level: PT;Classification code 10028245;Term: Multi ... | Product Name: Secukinumab Product Code: AIN457 | Novartis Pharma AG | NULL | Not Recruiting | Female: yes Male: yes | 380 | Phase 2 | United States;Portugal;Finland;Spain;Turkey;Russian Federation;Colombia;Switzerland;Italy;France;Czech Republic;Canada;Argentina;Poland;Belgium;Romania;Germany;Japan;Sweden United States;Portugal;Finland;Spain;Turkey;Russian Federation;Colombia;Switzerland;Italy;France;Cze ... | ||
| 2 | EUCTR2012-004019-29-DE (EUCTR) | 19/09/201320130919 | 06/05/201320130506 | Efficacy and safety of AIN457 to treat patients with relapsing multiple sclerosis | A Phase II, multicenter, randomized, double-blind, parallel group, placebo-controlled, adaptive dose-ranging study to evaluate the efficacy and safety of AIN457 in patients with relapsing multiple sclerosis A Phase II, multicenter, randomized, double-blind, parallel group, placebo-controlled, adaptive dose ... | Relapsing multiple sclerosis MedDRA version: 16.0;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Relapsing multiple sclerosis MedDRA version: 16.0;Level: PT;Classification code 10028245;Term: Multi ... | Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: Secukinumab Other descriptive name: Secukinumab Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: Secukinumab Other descriptive name: ... | Novartis Pharma AG | NULL | Not Recruiting | Female: yes Male: yes | 380 | Phase 2 | Portugal;United States;Finland;Spain;Turkey;Russian Federation;Colombia;Italy;Switzerland;France;Czech Republic;Canada;Argentina;Poland;Belgium;Romania;Germany;Japan;Sweden Portugal;United States;Finland;Spain;Turkey;Russian Federation;Colombia;Italy;Switzerland;France;Cze ... | ||
| 3 | EUCTR2012-004019-29-PT (EUCTR) | 02/08/201320130802 | 03/06/201320130603 | Efficacy and safety of AIN457 to treat patients with relapsing multiple sclerosis | A Phase II, multicenter, randomized, double-blind, parallel group, placebo-controlled, adaptive dose-ranging study to evaluate the efficacy and safety of AIN457 in patients with relapsing multiple sclerosis A Phase II, multicenter, randomized, double-blind, parallel group, placebo-controlled, adaptive dose ... | Relapsing multiple sclerosis MedDRA version: 14.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Relapsing multiple sclerosis MedDRA version: 14.1;Level: PT;Classification code 10028245;Term: Multi ... | Product Name: Secukinumab Product Code: AIN457 | Novartis Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 380 | Phase 2 | Portugal;United States;Finland;Spain;Turkey;Russian Federation;Colombia;Italy;Switzerland;France;Czech Republic;Canada;Argentina;Poland;Belgium;Romania;Germany;Japan;Sweden Portugal;United States;Finland;Spain;Turkey;Russian Federation;Colombia;Italy;Switzerland;France;Cze ... | ||
| 4 | EUCTR2012-004019-29-CZ (EUCTR) | 18/07/201320130718 | 13/05/201320130513 | Efficacy and safety of AIN457 to treat patients with relapsing multiple sclerosis | A Phase II, multicenter, randomized, double-blind, parallel group, placebo-controlled, adaptive dose-ranging study to evaluate the efficacy and safety of AIN457 in patients with relapsing multiple sclerosis A Phase II, multicenter, randomized, double-blind, parallel group, placebo-controlled, adaptive dose ... | Relapsing multiple sclerosis MedDRA version: 16.0;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Relapsing multiple sclerosis MedDRA version: 16.0;Level: PT;Classification code 10028245;Term: Multi ... | Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: Secukinumab Other descriptive name: SECUKINUMAB Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: Secukinumab Other descriptive name: ... | Novartis Pharma AG | NULL | Not Recruiting | Female: yes Male: yes | 380 | Phase 2 | Portugal;United States;Finland;Spain;Turkey;Russian Federation;Colombia;Italy;Switzerland;France;Czech Republic;Canada;Argentina;Poland;Belgium;Romania;Germany;Japan;Sweden Portugal;United States;Finland;Spain;Turkey;Russian Federation;Colombia;Italy;Switzerland;France;Cze ... | ||
| 5 | EUCTR2012-004019-29-IT (EUCTR) | 10/07/201320130710 | 11/01/201320130111 | Efficacy and safety of AIN457 to treat patients with relapsing multiple sclerosis | A Phase II, multicenter, randomized, double-blind, parallel group, placebocontrolled, adaptive dose-ranging study to evaluate the efficacy and safety of AIN457 in patients with relapsing multiple sclerosis A Phase II, multicenter, randomized, double-blind, parallel group, placebocontrolled, adaptive dose- ... | Relapsing multiple sclerosis MedDRA version: 14.1;Level: HLT;Classification code 10052785;Term: Multiple sclerosis acute and progressive;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 14.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;Classification code 10048393;Term: Multiple sclerosis relapse;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Relapsing multiple sclerosis MedDRA version: 14.1;Level: HLT;Classification code 10052785;Term: Mult ... | Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: Secukinumab Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: Secukinumab Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: Secukinumab Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: Secukinumab Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: Secukinumab Product Name: Secukinumab Product Code: AIN Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: Secukinumab Product Name: Secukinum ... | NOVARTIS FARMA | NULL | Not Recruiting | Female: yes Male: yes | 470 | Phase 2 | United States;Finland;Spain;Turkey;Russian Federation;Colombia;Italy;Switzerland;Canada;Argentina;Poland;Germany;Japan;Sweden United States;Finland;Spain;Turkey;Russian Federation;Colombia;Italy;Switzerland;Canada;Argentina;Po ... | ||
| 6 | EUCTR2012-004019-29-FI (EUCTR) | 19/06/201320130619 | 16/05/201320130516 | Efficacy and safety of AIN457 to treat patients with relapsing multiple sclerosis | A Phase II, multicenter, randomized, double-blind, parallel group, placebo-controlled, adaptive dose-ranging study to evaluate the efficacy and safety of AIN457 in patients with relapsing multiple sclerosis A Phase II, multicenter, randomized, double-blind, parallel group, placebo-controlled, adaptive dose ... | Relapsing multiple sclerosis MedDRA version: 14.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Relapsing multiple sclerosis MedDRA version: 14.1;Level: PT;Classification code 10028245;Term: Multi ... | Product Name: Secukinumab Product Code: AIN457 | Novartis Pharma AG | NULL | Not Recruiting | Female: yes Male: yes | 380 | Phase 2 | Portugal;United States;Finland;Spain;Turkey;Russian Federation;Colombia;Italy;Switzerland;France;Czech Republic;Canada;Argentina;Poland;Belgium;Romania;Germany;Japan;Sweden Portugal;United States;Finland;Spain;Turkey;Russian Federation;Colombia;Italy;Switzerland;France;Cze ... | ||
| 7 | EUCTR2012-004019-29-SE (EUCTR) | 19/06/201320130619 | 12/04/201320130412 | Efficacy and safety of AIN457 to treat patients with relapsing multiple sclerosis | A Phase II, multicenter, randomized, double-blind, parallel group, placebo-controlled, adaptive dose-ranging study to evaluate the efficacy and safety of AIN457 in patients with relapsing multiple sclerosis A Phase II, multicenter, randomized, double-blind, parallel group, placebo-controlled, adaptive dose ... | Relapsing multiple sclerosis MedDRA version: 14.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Relapsing multiple sclerosis MedDRA version: 14.1;Level: PT;Classification code 10028245;Term: Multi ... | Product Name: Secukinumab Product Code: AIN457 | Novartis Pharma AG | NULL | Not Recruiting | Female: yes Male: yes | 380 | Phase 2 | Portugal;United States;Finland;Spain;Turkey;Russian Federation;Colombia;Italy;Switzerland;France;Czech Republic;Canada;Argentina;Poland;Belgium;Romania;Germany;Japan;Sweden Portugal;United States;Finland;Spain;Turkey;Russian Federation;Colombia;Italy;Switzerland;France;Cze ... | ||
| 8 | JPRN-JapicCTI-132178 | 01/6/201320130601 | 00000000 | A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose ... | A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose ... | Multiple Sclerosis | Intervention name : AIN457 INN of the intervention : secukinumab Dosage And administration of the intervention : AIN457 will be administered intravenously. Patients will be randomized to AIN457 Low/Middle/High dose. Control intervention name : Placebo Dosage And administration of the control intervention : Matching placebo will be administered intravenously. Intervention name : AIN457 INN of the intervention : secukinumab Dosage And administration of the inte ... | Novartis Pharma K.K. | NULL | 18 | 55 | BOTH | 380 | Phase 2 | NULL | |
| 9 | NCT01874340 (ClinicalTrials.gov) | June 201320130600 | 28/5/201320130528 | Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis | A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose ... | Multiple Sclerosis | Drug: Placebo;Drug: AIN457 | Novartis Pharmaceuticals | NULL | Terminated | 18 Years | 55 Years | All | 28 | Phase 2 | Belgium;Czech Republic;France;Italy;Japan;Poland;Russian Federation;Spain;Sweden;Turkey;Canada;Finland;Germany;Romania;Switzerland;United States Belgium;Czech Republic;France;Italy;Japan;Poland;Russian Federation;Spain;Sweden;Turkey;Canada;Finla ... |
| 10 | EUCTR2012-004019-29-ES (EUCTR) | 24/05/201320130524 | 24/06/201320130624 | Efficacy and safety of AIN457 to treat patients with relapsing multiple sclerosis | A Phase II, multicenter, randomized, double-blind, parallel group, placebo-controlled, adaptive dose-ranging study to evaluate the efficacy and safety of AIN457 in patients with relapsing multiple sclerosis A Phase II, multicenter, randomized, double-blind, parallel group, placebo-controlled, adaptive dose ... | Relapsing multiple sclerosis MedDRA version: 14.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Relapsing multiple sclerosis MedDRA version: 14.1;Level: PT;Classification code 10028245;Term: Multi ... | Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: SECUKINUMAB Other descriptive name: SECUKINUMAB Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: SECUKINUMAB Other descriptive name: ... | Novartis Farmacéutica, S.A. | NULL | Not Recruiting | Female: yes Male: yes | 380 | Phase 2 | Portugal;United States;Finland;Spain;Turkey;Russian Federation;Colombia;Italy;Switzerland;France;Czech Republic;Canada;Argentina;Poland;Belgium;Romania;Germany;Japan;Sweden Portugal;United States;Finland;Spain;Turkey;Russian Federation;Colombia;Italy;Switzerland;France;Cze ... |
37. 膿疱性乾癬（汎発型）
臨床試験数 : 79 / 薬物数 : 57 - (DrugBank : 21) / 標的遺伝子数 : 20 - 標的パスウェイ数 : 102
Showing 1 to 9 of 9 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2013-003086-34-PL (EUCTR) | 18/04/201420140418 | 10/03/201420140310 | Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects with Moderate to Severe Chronic Palmoplantar Pustular Psoriasis Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects with Moderate to Severe Chron ... | A 52-week, multicenter, randomized, double-blind, placebo-controlled study of subcutaneous secukinumab to demonstrate efficacy as assessed by palmoplantar pustulosis Psoriasis Area and Severity Index (ppPASI) at 16 weeks of treatment, compared to placebo, and to assess long-term safety, tolerability, and efficacy in subjects with moderate to severe chronic palmoplantar pustular psoriasis - amended with an optional extension treatment period of up to a total of 148 weeks A 52-week, multicenter, randomized, double-blind, placebo-controlled study of subcutaneous secukinum ... | moderate to severe chronic palmoplantar pustular psoriasis MedDRA version: 17.1;Level: PT;Classification code 10037575;Term: Pustular psoriasis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders MedDRA version: 17.1;Level: LLT;Classification code 10037158;Term: Psoriasis palm & soles;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] moderate to severe chronic palmoplantar pustular psoriasis MedDRA version: 17.1;Level: PT;Classifica ... | Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: SECUKINUMAB Other descriptive name: SECUKINUMAB Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: SECUKINUMAB Other descriptive name: ... | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 210 | Phase 3 | France;Belgium;Spain;Poland;Austria;Russian Federation;Germany;Italy;United Kingdom;Sweden | ||
| 2 | EUCTR2013-003086-34-IT (EUCTR) | 04/03/201420140304 | 12/12/201320131212 | Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects with Moderate to Severe Chronic Palmoplantar Pustular Psoriasis Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects with Moderate to Severe Chron ... | A 52-week, multicenter, randomized, double-blind, placebo-controlled study of subcutaneous secukinumab to demonstrate efficacy as assessed by palmoplantar pustulosis Psoriasis Area and Severity Index (ppPASI) at 16 weeks of treatment, compared to placebo, and to assess long-term safety, tolerability, and efficacy in subjects with moderate to severe chronic palmoplantar pustular psoriasis A 52-week, multicenter, randomized, double-blind, placebo-controlled study of subcutaneous secukinum ... | moderate to severe chronic palmoplantar pustular psoriasis MedDRA version: 14.1;Level: PT;Classification code 10037575;Term: Pustular psoriasis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders MedDRA version: 14.1;Level: LLT;Classification code 10037158;Term: Psoriasis palm & soles;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] moderate to severe chronic palmoplantar pustular psoriasis MedDRA version: 14.1;Level: PT;Classifica ... | Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: SECUKINUMAB Other descriptive name: SECUKINUMAB Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: SECUKINUMAB Other descriptive name: ... | NOVARTIS FARMA S.p.A. | NULL | Not Recruiting | Female: yes Male: yes | 210 | Phase 3 | France;Belgium;Spain;Poland;Austria;Russian Federation;Germany;United Kingdom;Italy;Sweden | ||
| 3 | EUCTR2013-003086-34-BE (EUCTR) | 10/02/201420140210 | 09/12/201320131209 | Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects with Moderate to Severe Chronic Palmoplantar Pustular Psoriasis Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects with Moderate to Severe Chron ... | A 52-week, multicenter, randomized, double-blind, placebo-controlledstudy of subcutaneous secukinumab to demonstrate efficacy as assessedby palmoplantar pustulosis Psoriasis Area and Severity Index (ppPASI) at16 weeks of treatment, compared to placebo, and to assess long-termsafety, tolerability, and efficacy in subjects with moderate to severechronic palmoplantar pustular psoriasis - amended with an optionalextension treatment period of up to a total of 148 weeks A 52-week, multicenter, randomized, double-blind, placebo-controlledstudy of subcutaneous secukinuma ... | moderate to severe chronic palmoplantar pustular psoriasis MedDRA version: 20.0;Level: PT;Classification code 10037575;Term: Pustular psoriasis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders MedDRA version: 20.0;Level: LLT;Classification code 10037158;Term: Psoriasis palm & soles;System Organ Class: 100000018190;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] moderate to severe chronic palmoplantar pustular psoriasis MedDRA version: 20.0;Level: PT;Classifica ... | Product Name: Secukinumab 150 mg/1 mL Solution for injection Product Code: AIN457 INN or Proposed INN: SECUKINUMAB Other descriptive name: SECUKINUMAB Product Name: Secukinumab 150 mg/1 mL Solution for injection Product Code: AIN457 INN or Proposed INN: ... | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 210 | Phase 3 | France;Poland;Spain;Belgium;Austria;Russian Federation;Germany;Italy;United Kingdom;Sweden | ||
| 4 | EUCTR2013-003086-34-DE (EUCTR) | 27/12/201320131227 | 05/12/201320131205 | Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects with Moderate to Severe Chronic Palmoplantar Pustular Psoriasis Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects with Moderate to Severe Chron ... | A 52-week, multicenter, randomized, double-blind, placebo-controlled study of subcutaneous secukinumab to demonstrate efficacy as assessed by palmoplantar pustulosis Psoriasis Area and Severity Index (ppPASI) at 16 weeks of treatment, compared to placebo, and to assess long-term safety, tolerability, and efficacy in subjects with moderate to severe chronic palmoplantar pustular psoriasis - amended with an optional extension treatment period of up to a total of 148 weeks A 52-week, multicenter, randomized, double-blind, placebo-controlled study of subcutaneous secukinum ... | moderate to severe chronic palmoplantar pustular psoriasis MedDRA version: 19.0;Level: PT;Classification code 10037575;Term: Pustular psoriasis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders MedDRA version: 19.0;Level: LLT;Classification code 10037158;Term: Psoriasis palm & soles;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] moderate to severe chronic palmoplantar pustular psoriasis MedDRA version: 19.0;Level: PT;Classifica ... | Product Name: Secukinumab Product Code: AIN457, 150mg INN or Proposed INN: SECUKINUMAB Other descriptive name: SECUKINUMAB Product Name: Secukinumab Product Code: AIN457, 150mg INN or Proposed INN: SECUKINUMAB Other descriptiv ... | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 210 | Phase 3 | France;Poland;Belgium;Spain;Austria;Russian Federation;Germany;Italy;United Kingdom;Sweden | ||
| 5 | EUCTR2013-003086-34-AT (EUCTR) | 17/12/201320131217 | 28/11/201320131128 | Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects with Moderate to Severe Chronic Palmoplantar Pustular Psoriasis Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects with Moderate to Severe Chron ... | A 52-week, multicenter, randomized, double-blind, placebo-controlled study of subcutaneous secukinumab to demonstrate efficacy as assessed by palmoplantar pustulosis Psoriasis Area and Severity Index (ppPASI) at 16 weeks of treatment, compared to placebo, and to assess long-term safety, tolerability, and efficacy in subjects with moderate to severe chronic palmoplantar pustular psoriasis - amended with an optional extension treatment period of up to a total of 148 weeks A 52-week, multicenter, randomized, double-blind, placebo-controlled study of subcutaneous secukinum ... | moderate to severe chronic palmoplantar pustular psoriasis MedDRA version: 18.0;Level: PT;Classification code 10037575;Term: Pustular psoriasis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders MedDRA version: 18.0;Level: LLT;Classification code 10037158;Term: Psoriasis palm & soles;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] moderate to severe chronic palmoplantar pustular psoriasis MedDRA version: 18.0;Level: PT;Classifica ... | Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: SECUKINUMAB Other descriptive name: SECUKINUMAB Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: SECUKINUMAB Other descriptive name: ... | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 210 | Phase 3 | France;Poland;Belgium;Spain;Austria;Russian Federation;Germany;Italy;United Kingdom;Sweden | ||
| 6 | EUCTR2013-003086-34-GB (EUCTR) | 12/12/201320131212 | 28/11/201320131128 | Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects with Moderate to Severe Chronic Palmoplantar Pustular Psoriasis Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects with Moderate to Severe Chron ... | A 52-week, multicenter, randomized, double-blind, placebo-controlled study of subcutaneous secukinumab to demonstrate efficacy as assessed by palmoplantar pustulosis Psoriasis Area and Severity Index (ppPASI) at 16 weeks of treatment, compared to placebo, and to assess long-term safety, tolerability, and efficacy in subjects with moderate to severe chronic palmoplantar pustular psoriasis - amended with an optional extension treatment period of up to a total of 148 weeks. A 52-week, multicenter, randomized, double-blind, placebo-controlled study of subcutaneous secukinum ... | moderate to severe chronic palmoplantar pustular psoriasis MedDRA version: 17.1;Level: PT;Classification code 10037575;Term: Pustular psoriasis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders MedDRA version: 17.1;Level: LLT;Classification code 10037158;Term: Psoriasis palm & soles;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] moderate to severe chronic palmoplantar pustular psoriasis MedDRA version: 17.1;Level: PT;Classifica ... | Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: SECUKINUMAB Other descriptive name: SECUKINUMAB Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: SECUKINUMAB Other descriptive name: ... | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 210 | Phase 3 | France;Poland;Belgium;Spain;Austria;Russian Federation;Germany;Italy;United Kingdom;Sweden | ||
| 7 | EUCTR2013-003086-34-ES (EUCTR) | 09/12/201320131209 | 05/12/201320131205 | Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects with Moderate to Severe Chronic Palmoplantar Pustular Psoriasis. Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects with Moderate to Severe Chron ... | A 52-week, multicenter, randomized, double-blind, placebo-controlled study of subcutaneous secukinumab to demonstrate efficacy as assessed by palmoplantar pustulosis Psoriasis Area and Severity Index (ppPASI) at 16 weeks of treatment, compared to placebo, and to assess long-term safety, tolerability, and efficacy in subjects with moderate to severe chronic palmoplantar pustular psoriasis. A 52-week, multicenter, randomized, double-blind, placebo-controlled study of subcutaneous secukinum ... | Moderate to severe chronic palmoplantar pustular psoriasis. MedDRA version: 14.1;Level: PT;Classification code 10037575;Term: Pustular psoriasis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders MedDRA version: 14.1;Level: LLT;Classification code 10037158;Term: Psoriasis palm & soles;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] Moderate to severe chronic palmoplantar pustular psoriasis. MedDRA version: 14.1;Level: PT;Classific ... | Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: Secukinumab Other descriptive name: SECUKINUMAB Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: Secukinumab Other descriptive name: ... | Novartis Farmacéutica, S.A. | NULL | Not Recruiting | Female: yes Male: yes | 210 | Phase 3 | France;Belgium;Poland;Spain;Austria;Russian Federation;Germany;Italy;United Kingdom;Sweden | ||
| 8 | EUCTR2013-003086-34-SE (EUCTR) | 04/12/201320131204 | 22/11/201320131122 | Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects with Moderate to Severe Chronic Palmoplantar Pustular Psoriasis Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects with Moderate to Severe Chron ... | A 52-week, multicenter, randomized, double-blind, placebo-controlled study of subcutaneous secukinumab to demonstrate efficacy as assessed by palmoplantar pustulosis Psoriasis Area and Severity Index (ppPASI) at 16 weeks of treatment, compared to placebo, and to assess long-term safety, tolerability, and efficacy in subjects with moderate to severe chronic palmoplantar pustular psoriasis A 52-week, multicenter, randomized, double-blind, placebo-controlled study of subcutaneous secukinum ... | Moderate to severe chronic palmoplantar pustular psoriasis MedDRA version: 16.1;Level: PT;Classification code 10037575;Term: Pustular psoriasis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders MedDRA version: 16.1;Level: LLT;Classification code 10037158;Term: Psoriasis palm & soles;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] Moderate to severe chronic palmoplantar pustular psoriasis MedDRA version: 16.1;Level: PT;Classifica ... | Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: SECUKINUMAB Other descriptive name: SECUKINUMAB Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: SECUKINUMAB Other descriptive name: ... | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 210 | Phase 3 | France;Spain;Belgium;Poland;Austria;Russian Federation;Germany;United Kingdom;Italy;Sweden | ||
| 9 | JPRN-JapicCTI-132305 | 01/8/201320130801 | 18/10/201320131018 | Study to assess the efficacy, safety and tolerability of secukinumab in Japanese subjects with GPP | A multi-center, open label study of subcutaneous secukinumab in prefilled syringes as mono- or co-therapy to assess the efficacy, safety and tolerability up to 52 weeks in Japanese subjects with generalized pustular psoriasis A multi-center, open label study of subcutaneous secukinumab in prefilled syringes as mono- or co-th ... | Generalized Pustular Psoriasis (GPP) | Intervention name : AIN457 INN of the intervention : Secukinumab Dosage And administration of the intervention : Secukinumab 150 mg, provided in a 1 mL prefilled syringe (one syringe for 150 mg dose, two syringes for the 300 mg dose) Control intervention name : null Intervention name : AIN457 INN of the intervention : Secukinumab Dosage And administration of the int ... | Novartis Pharma K.K. | NULL | 18 | BOTH | Phase 3 | NULL |
41. 巨細胞性動脈炎
臨床試験数 : 131 / 薬物数 : 139 - (DrugBank : 36) / 標的遺伝子数 : 33 - 標的パスウェイ数 : 125
Showing 1 to 10 of 11 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2020-004809-31-SE (EUCTR) | 11/01/202220220111 | 21/10/202120211021 | Study of efficacy and safety of secukinumab 300 mg and 150 mg in patients with giant cell arteritis (GCA). Study of efficacy and safety of secukinumab 300 mg and 150 mg in patients with giant cell arteritis ... | A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to investigate the efficacy and safety of secukinumab 300 mg and 150 mg administered subcutaneously versus placebo, in combination with aglucocorticoid taper regimen, in patients with giant cell arteritis (GCA) A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to inves ... | giant cell arteritis MedDRA version: 23.1;Level: PT;Classification code 10018250;Term: Giant cell arteritis;System Organ Class: 10047065 - Vascular disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] giant cell arteritis MedDRA version: 23.1;Level: PT;Classification code 10018250;Term: Giant cell ar ... | Trade Name: Cosentyx 300 mg solution for injection in pre-filled syringe INN or Proposed INN: SECUKINUMAB Trade Name: PredniSONE Tablets, USP, 1 mg INN or Proposed INN: Prednisone Other descriptive name: PREDNISONE Trade Name: PredniSONE Tablets, USP 2.5 mg INN or Proposed INN: Prednisone Other descriptive name: PREDNISONE Trade Name: PredniSONE Tablets, USP 5 mg INN or Proposed INN: Prednisone Other descriptive name: PREDNISONE Trade Name: PredniSONE Tablets, USP 10 mg INN or Proposed INN: Prednisone Other descriptive name: PREDNISONE Trade Name: Cosentyx 300 mg solution for injection in pre-filled syringe INN or Proposed INN: SECUKIN ... | Novartis Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 348 | Phase 3 | United States;Portugal;Estonia;Spain;Russian Federation;Switzerland;Italy;France;Australia;Denmark;South Africa;Netherlands;Czechia;Finland;Guatemala;Turkey;United Kingdom;Hungary;Canada;Argentina;Poland;Brazil;Belgium;Bulgaria;Germany;Norway;New Zealand;Sweden United States;Portugal;Estonia;Spain;Russian Federation;Switzerland;Italy;France;Australia;Denmark;S ... | ||
| 2 | EUCTR2020-004809-31-DK (EUCTR) | 18/11/202120211118 | 01/08/202120210801 | Study of efficacy and safety of secukinumab 300 mg in patients with giant cell arteritis (GCA). | A randomized, parallel-group, double-blind, placebo-controlled,multicenter Phase III trial to investigate theefficacy and safety of secukinumab 300 mg administeredsubcutaneously versus placebo, in combination with aglucocorticoid taper regimen, in patients with giant cellarteritis (GCA) A randomized, parallel-group, double-blind, placebo-controlled,multicenter Phase III trial to invest ... | giant cell arteritis MedDRA version: 23.1;Level: PT;Classification code 10018250;Term: Giant cell arteritis;System Organ Class: 10047065 - Vascular disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] giant cell arteritis MedDRA version: 23.1;Level: PT;Classification code 10018250;Term: Giant cell ar ... | Trade Name: Cosentyx 300 mg solution for injection in pre-filled syringe INN or Proposed INN: SECUKINUMAB Trade Name: PredniSONE Tablets USP, 1 mg INN or Proposed INN: Prednisone Other descriptive name: PREDNISONE Trade Name: PredniSONE Tablets USP, 2.5 mg INN or Proposed INN: Prednisone Other descriptive name: PREDNISONE Trade Name: PredniSONE Tablets USP, 5 mg INN or Proposed INN: Prednisone Other descriptive name: PREDNISONE Trade Name: PredniSONE Tablets USP, 10 mg INN or Proposed INN: Prednisone Other descriptive name: PREDNISONE Trade Name: Cosentyx 300 mg solution for injection in pre-filled syringe INN or Proposed INN: SECUKIN ... | Novartis Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 240 | Phase 3 | United States;Portugal;Estonia;Spain;Russian Federation;Italy;Switzerland;France;Australia;Denmark;South Africa;Netherlands;Czechia;Finland;Guatemala;Turkey;United Kingdom;Hungary;Canada;Argentina;Brazil;Belgium;Poland;Bulgaria;Germany;Norway;New Zealand;Sweden United States;Portugal;Estonia;Spain;Russian Federation;Italy;Switzerland;France;Australia;Denmark;S ... | ||
| 3 | EUCTR2020-004809-31-NO (EUCTR) | 16/11/202120211116 | 28/06/202120210628 | Study of efficacy and safety of secukinumab 300 mg in patients with giant cell arteritis (GCA). | A randomized, parallel-group, double-blind, placebo-controlled,multicenter Phase III trial to investigate theefficacy and safety of secukinumab 300 mg administeredsubcutaneously versus placebo, in combination with aglucocorticoid taper regimen, in patients with giant cellarteritis (GCA) A randomized, parallel-group, double-blind, placebo-controlled,multicenter Phase III trial to invest ... | giant cell arteritis MedDRA version: 23.1;Level: PT;Classification code 10018250;Term: Giant cell arteritis;System Organ Class: 10047065 - Vascular disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] giant cell arteritis MedDRA version: 23.1;Level: PT;Classification code 10018250;Term: Giant cell ar ... | Trade Name: Cosentyx 300 mg solution for injection in pre-filled syringe Product Name: Cosentyx Product Code: AIN457 INN or Proposed INN: SECUKINUMAB Trade Name: PredniSONE Tablets USP, 1 mg Product Name: Prednisone INN or Proposed INN: Prednisone Other descriptive name: PREDNISONE Trade Name: PredniSONE Tablets USP, 2.5 mg Product Name: Prednisone INN or Proposed INN: Prednisone Other descriptive name: PREDNISONE Trade Name: PredniSONE Tablets USP, 5 mg Product Name: Prednisone INN or Proposed INN: Prednisone Other descriptive name: PREDNISONE Trade Name: PredniSONE Tablets USP, 10 mg Product Name: Prednisone INN or Proposed INN: Prednisone Other descriptive name: PREDNISONE Trade Name: Cosentyx 300 mg solution for injection in pre-filled syringe Product Name: Cosentyx Produc ... | Novartis Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 240 | Phase 3 | United States;Portugal;Estonia;Spain;Russian Federation;Italy;Switzerland;France;Denmark;Australia;South Africa;Netherlands;Czechia;Finland;Guatemala;Turkey;United Kingdom;Hungary;Canada;Argentina;Brazil;Belgium;Poland;Bulgaria;Germany;Norway;New Zealand;Sweden United States;Portugal;Estonia;Spain;Russian Federation;Italy;Switzerland;France;Denmark;Australia;S ... | ||
| 4 | EUCTR2020-004809-31-BG (EUCTR) | 08/11/202120211108 | 26/08/202120210826 | Study of efficacy and safety of secukinumab 300 mg in patients with giant cell arteritis (GCA). | A randomized, parallel-group, double-blind, placebo-controlled,multicenter Phase III trial to investigate theefficacy and safety of secukinumab 300 mg administeredsubcutaneously versus placebo, in combination with aglucocorticoid taper regimen, in patients with giant cellarteritis (GCA) A randomized, parallel-group, double-blind, placebo-controlled,multicenter Phase III trial to invest ... | giant cell arteritis MedDRA version: 23.1;Level: PT;Classification code 10018250;Term: Giant cell arteritis;System Organ Class: 10047065 - Vascular disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] giant cell arteritis MedDRA version: 23.1;Level: PT;Classification code 10018250;Term: Giant cell ar ... | Trade Name: Cosentyx 300mg solution for injection in pre-filled syringe INN or Proposed INN: SECUKINUMAB Trade Name: PredniSONE Tablets USP, 1mg INN or Proposed INN: Prednisone Other descriptive name: PREDNISONE Trade Name: PredniSONE Tablets USP, 2.5mg INN or Proposed INN: Prednisone Other descriptive name: PREDNISONE Trade Name: PredniSONE Tablets USP, 5mg INN or Proposed INN: Prednisone Other descriptive name: PREDNISONE Trade Name: PredniSONE Tablets USP, 20mg INN or Proposed INN: Prednisone Other descriptive name: PREDNISONE Trade Name: Cosentyx 300mg solution for injection in pre-filled syringe INN or Proposed INN: SECUKINU ... | Novartis Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 240 | Phase 3 | United States;Portugal;Estonia;Spain;Russian Federation;Italy;Switzerland;France;Denmark;Australia;South Africa;Netherlands;Czechia;Finland;Guatemala;Turkey;United Kingdom;Hungary;Canada;Argentina;Brazil;Belgium;Poland;Bulgaria;Germany;Norway;New Zealand;Sweden United States;Portugal;Estonia;Spain;Russian Federation;Italy;Switzerland;France;Denmark;Australia;S ... | ||
| 5 | EUCTR2020-004809-31-DE (EUCTR) | 19/10/202120211019 | 12/07/202120210712 | Study of efficacy and safety of secukinumab 300 mg in patients with giant cell arteritis (GCA). | A randomized, parallel-group, double-blind, placebo-controlled,multicenter Phase III trial to investigate theefficacy and safety of secukinumab 300 mg administeredsubcutaneously versus placebo, in combination with aglucocorticoid taper regimen, in patients with giant cellarteritis (GCA) A randomized, parallel-group, double-blind, placebo-controlled,multicenter Phase III trial to invest ... | giant cell arteritis MedDRA version: 23.1;Level: PT;Classification code 10018250;Term: Giant cell arteritis;System Organ Class: 10047065 - Vascular disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] giant cell arteritis MedDRA version: 23.1;Level: PT;Classification code 10018250;Term: Giant cell ar ... | Trade Name: Cosentyx 300 mg solution for injection in pre-filled syringe INN or Proposed INN: SECUKINUMAB Trade Name: PredniSONE Tablets USP, 1 mg INN or Proposed INN: Prednisone Other descriptive name: PREDNISONE Trade Name: PredniSONE Tablets USP, 2.5 mg INN or Proposed INN: Prednisone Other descriptive name: PREDNISONE Trade Name: PredniSONE Tablets USP, 5 mg INN or Proposed INN: Prednisone Other descriptive name: PREDNISONE Trade Name: PredniSONE Tablets USP, 10 mg INN or Proposed INN: Prednisone Other descriptive name: PREDNISONE Trade Name: Cosentyx 300 mg solution for injection in pre-filled syringe INN or Proposed INN: SECUKIN ... | Novartis Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 240 | Phase 3 | United States;Portugal;Estonia;Spain;Russian Federation;Italy;Switzerland;France;Denmark;Australia;South Africa;Netherlands;Czechia;Finland;Guatemala;Turkey;United Kingdom;Hungary;Canada;Argentina;Brazil;Belgium;Poland;Bulgaria;Germany;Norway;New Zealand;Sweden United States;Portugal;Estonia;Spain;Russian Federation;Italy;Switzerland;France;Denmark;Australia;S ... | ||
| 6 | EUCTR2020-004809-31-PT (EUCTR) | 13/10/202120211013 | 07/07/202120210707 | Study of efficacy and safety of secukinumab 300 mg and 150 mg in patients with giant cell arteritis (GCA). Study of efficacy and safety of secukinumab 300 mg and 150 mg in patients with giant cell arteritis ... | A randomized, parallel-group, double-blind, placebo-controlled,multicenter Phase III trial to investigate the efficacy and safety of secukinumab 300 mg and 150 mg administered subcutaneously versus placebo, in combination with a glucocorticoid taper regimen, in patients with giant cell arteritis (GCA) A randomized, parallel-group, double-blind, placebo-controlled,multicenter Phase III trial to invest ... | giant cell arteritis MedDRA version: 23.1;Level: PT;Classification code 10018250;Term: Giant cell arteritis;System Organ Class: 10047065 - Vascular disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] giant cell arteritis MedDRA version: 23.1;Level: PT;Classification code 10018250;Term: Giant cell ar ... | Trade Name: Cosentyx 300 mg solution for injection in pre-filled syringe INN or Proposed INN: SECUKINUMAB Trade Name: PredniSONE Tablets USP, 1 mg INN or Proposed INN: Prednisone Other descriptive name: PREDNISONE Trade Name: PredniSONE Tablets USP, 2.5 mg INN or Proposed INN: Prednisone Other descriptive name: PREDNISONE Trade Name: PredniSONE Tablets USP, 5 mg INN or Proposed INN: Prednisone Other descriptive name: PREDNISONE Trade Name: PredniSONE Tablets USP, 10 mg INN or Proposed INN: Prednisone Other descriptive name: PREDNISONE Trade Name: Cosentyx 300 mg solution for injection in pre-filled syringe INN or Proposed INN: SECUKIN ... | Novartis Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 348 | Phase 3 | Russian Federation;United States;Czechia;Portugal;Sweden;Netherlands;Brazil;Guatemala;Poland;France;Bulgaria;Argentina;Hungary;United Kingdom;Switzerland;Spain;New Zealand;Canada;Turkey;Belgium;Norway;Finland;Denmark;South Africa;Italy;Australia;Germany;Estonia Russian Federation;United States;Czechia;Portugal;Sweden;Netherlands;Brazil;Guatemala;Poland;France; ... | ||
| 7 | EUCTR2020-004809-31-FI (EUCTR) | 05/10/202120211005 | 16/07/202120210716 | Study of efficacy and safety of secukinumab 300 mg in patients with giant cell arteritis (GCA). | A randomized, parallel-group, double-blind, placebo-controlled,multicenter Phase III trial to investigate theefficacy and safety of secukinumab 300 mg administeredsubcutaneously versus placebo, in combination with aglucocorticoid taper regimen, in patients with giant cellarteritis (GCA) A randomized, parallel-group, double-blind, placebo-controlled,multicenter Phase III trial to invest ... | giant cell arteritis MedDRA version: 23.1;Level: PT;Classification code 10018250;Term: Giant cell arteritis;System Organ Class: 10047065 - Vascular disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] giant cell arteritis MedDRA version: 23.1;Level: PT;Classification code 10018250;Term: Giant cell ar ... | Trade Name: Cosentyx 300 mg solution for injection in pre-filled syringe INN or Proposed INN: SECUKINUMAB Trade Name: PredniSONE Tablets USP, 1 mg INN or Proposed INN: Prednisone Other descriptive name: PREDNISONE Trade Name: PredniSONE Tablets USP, 2.5 mg INN or Proposed INN: Prednisone Other descriptive name: PREDNISONE Trade Name: PredniSONE Tablets USP, 5 mg INN or Proposed INN: Prednisone Other descriptive name: PREDNISONE Trade Name: PredniSONE Tablets USP, 10 mg INN or Proposed INN: Prednisone Other descriptive name: PREDNISONE Trade Name: Cosentyx 300 mg solution for injection in pre-filled syringe INN or Proposed INN: SECUKIN ... | Novartis Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 240 | Phase 3 | United States;Portugal;Estonia;Spain;Russian Federation;Italy;Switzerland;France;Denmark;Australia;South Africa;Netherlands;Czechia;Finland;Guatemala;Turkey;United Kingdom;Hungary;Canada;Argentina;Brazil;Belgium;Poland;Bulgaria;Germany;Norway;New Zealand;Sweden United States;Portugal;Estonia;Spain;Russian Federation;Italy;Switzerland;France;Denmark;Australia;S ... | ||
| 8 | EUCTR2020-004809-31-FR (EUCTR) | 24/09/202120210924 | 22/06/202120210622 | Study of efficacy and safety of secukinumab 300 mg in patients with giant cell arteritis (GCA). | A randomized, parallel-group, double-blind, placebo-controlled,multicenter Phase III trial to investigate theefficacy and safety of secukinumab 300 mg administeredsubcutaneously versus placebo, in combination with aglucocorticoid taper regimen, in patients with giant cellarteritis (GCA) A randomized, parallel-group, double-blind, placebo-controlled,multicenter Phase III trial to invest ... | giant cell arteritis MedDRA version: 23.1;Level: PT;Classification code 10018250;Term: Giant cell arteritis;System Organ Class: 10047065 - Vascular disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] giant cell arteritis MedDRA version: 23.1;Level: PT;Classification code 10018250;Term: Giant cell ar ... | Trade Name: Cosentyx Product Name: Cosentyx Product Code: AIN457 INN or Proposed INN: SECUKINUMAB Trade Name: Prednisone Product Name: Prednisone INN or Proposed INN: Prednisone Other descriptive name: PREDNISONE Trade Name: Prednisone Product Name: Prednisone INN or Proposed INN: Prednisone Other descriptive name: PREDNISONE Trade Name: Prednisone Product Name: Prednisone INN or Proposed INN: Prednisone Other descriptive name: PREDNISONE Trade Name: Prednisone Product Name: Prednisone INN or Proposed INN: Prednisone Other descriptive name: PREDNISONE Trade Name: Cosentyx Product Name: Cosentyx Product Code: AIN457 INN or Proposed INN: SECUKINUMAB Trade ... | Novartis Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 240 | Phase 3 | United States;Portugal;Estonia;Spain;Russian Federation;Italy;Switzerland;France;Denmark;Australia;South Africa;Netherlands;Czechia;Finland;Guatemala;Turkey;United Kingdom;Hungary;Canada;Argentina;Belgium;Brazil;Poland;Bulgaria;Germany;Norway;New Zealand;Sweden United States;Portugal;Estonia;Spain;Russian Federation;Italy;Switzerland;France;Denmark;Australia;S ... | ||
| 9 | EUCTR2020-004809-31-IT (EUCTR) | 16/09/202120210916 | 22/10/202120211022 | Study of efficacy and safety of secukinumab 300 mg in patients with giant cell arteritis (GCA). | A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to investigate the efficacy and safety of secukinumab 300 mg administered subcutaneously versus placebo, in combination with a glucocorticoid taper regimen, in patients with giant cell arteritis (GCA) - - A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to inves ... | Giant cell arteritis MedDRA version: 23.1;Level: PT;Classification code 10018250;Term: Giant cell arteritis;System Organ Class: 10047065 - Vascular disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Giant cell arteritis MedDRA version: 23.1;Level: PT;Classification code 10018250;Term: Giant cell ar ... | Trade Name: Prednisone Product Name: Prednisone Product Code: [-] INN or Proposed INN: PREDNISONE Trade Name: Prednisone Product Name: Prednisone Product Code: [-] INN or Proposed INN: PREDNISONE Trade Name: Prednisone Product Name: Prednisone Product Code: [-] INN or Proposed INN: PREDNISONE Trade Name: Prednisone Product Name: Prednisone Product Code: [-] INN or Proposed INN: PREDNISONE Trade Name: Cosentyx Product Name: Cosentyx Product Code: [AIN457] INN or Proposed INN: SECUKINUMAB Trade Name: Prednisone Product Name: Prednisone Product Code: [-] INN or Proposed INN: PREDNISONE Trade ... | NOVARTIS PHARMA AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 240 | Phase 3 | United States;Portugal;Spain;Russian Federation;Italy;Switzerland;France;Denmark;Australia;South Africa;Netherlands;Czechia;Finland;Guatemala;Turkey;United Kingdom;Hungary;Canada;Argentina;Belgium;Brazil;Poland;Bulgaria;Germany;Norway;New Zealand;Sweden United States;Portugal;Spain;Russian Federation;Italy;Switzerland;France;Denmark;Australia;South Afr ... | ||
| 10 | NCT03765788 (ClinicalTrials.gov) | January 30, 201920190130 | 3/12/201820181203 | A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Ce ... | A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab (AIN457) in Patients With Giant Cell Arteritis (TitAIN) A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial to Investi ... | Giant Cell Arteritis | Drug: Secukinumab 300 mg, s.c.;Drug: Prednisolone;Drug: Placebo | Novartis Pharmaceuticals | NULL | Completed | 50 Years | N/A | All | 52 | Phase 2 | Germany |
46. 悪性関節リウマチ
臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228
Showing 1 to 10 of 48 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2013-000944-25-HU (EUCTR) | 19/09/201320130919 | 16/07/201320130716 | Extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in patients with rheumatoid arthritis Extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in patien ... | A three year extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in subjects with active rheumatoid arthritis - REASSURE-1 Extension A three year extension study to evaluate the long term efficacy, safety and tolerability of secukinu ... | Rheumatoid arthritis MedDRA version: 14.1;Level: PT;Classification code 10039073;Term: Rheumatoid arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Rheumatoid arthritis MedDRA version: 14.1;Level: PT;Classification code 10039073;Term: Rheumatoid ar ... | Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: Secukinumab | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 454 | Panama;United States;Thailand;Guatemala;Colombia;Italy;India;Hungary;Mexico;Canada;Argentina;Belgium;Japan Panama;United States;Thailand;Guatemala;Colombia;Italy;India;Hungary;Mexico;Canada;Argentina;Belgium ... | |||
| 2 | JPRN-JapicCTI-132209 | 01/9/201320130901 | 00000000 | Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA (REASSURE-E) Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA ( ... | A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinu ... | Rheumatoid Arthritis | Intervention name : AIN457 INN of the intervention : Secukinumab Dosage And administration of the intervention : Subjects will receive 150 mg secukinumab s.c. Control intervention name : null Intervention name : AIN457 INN of the intervention : Secukinumab Dosage And administration of the int ... | Novartis Pharma K.K. | NULL | 18 | BOTH | 454 | Phase 3 | NULL | ||
| 3 | NCT01901900 (ClinicalTrials.gov) | September 201320130900 | 10/7/201320130710 | Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA. | A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinu ... | Rheumatoid Arthritis | Biological: Secukinumab (AIN457) | Novartis Pharmaceuticals | NULL | Completed | 18 Years | N/A | Both | 196 | Phase 3 | United States;Argentina;Canada;Guatemala;Hungary;India;Italy;Japan;Mexico;Thailand;Colombia;Panama;Puerto Rico United States;Argentina;Canada;Guatemala;Hungary;India;Italy;Japan;Mexico;Thailand;Colombia;Panama;P ... |
| 4 | EUCTR2013-000944-25-IT (EUCTR) | 02/08/201320130802 | 06/06/201320130606 | Extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in patients with rheumatoid arthritis Extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in patien ... | A three year extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in subjects with active rheumatoid arthritis - REASSURE-1 Extension A three year extension study to evaluate the long term efficacy, safety and tolerability of secukinu ... | Rheumatoid arthritis MedDRA version: 16.0;Level: PT;Classification code 10039073;Term: Rheumatoid arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Rheumatoid arthritis MedDRA version: 16.0;Level: PT;Classification code 10039073;Term: Rheumatoid ar ... | Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: Secukinumab | Novartis Farma S.p.A. | NULL | Not Recruiting | Female: yes Male: yes | 454 | Panama;United States;Thailand;Guatemala;Colombia;Italy;India;Hungary;Mexico;Canada;Argentina;Belgium;Japan Panama;United States;Thailand;Guatemala;Colombia;Italy;India;Hungary;Mexico;Canada;Argentina;Belgium ... | |||
| 5 | EUCTR2011-006058-94-DE (EUCTR) | 04/03/201320130304 | 27/08/201220120827 | Secukinumab efficacy and safety study in patients with active Rheumatoid Arthritis (RA) and an Inadequate response to anti-TNFa agents Secukinumab efficacy and safety study in patients with active Rheumatoid Arthritis (RA) and an Inade ... | A Phase III randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab in prefilled syringes to demonstrate the efficacy at 24 weeks and to assess the long term efficacy, safety, tolerability and usability up to 5 years in patients with active rheumatoid arthritis who have an inadequate response to anti-TNFa agents - REASSURE 2 A Phase III randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinum ... | Rheumatoid arthritis MedDRA version: 16.1;Level: PT;Classification code 10039073;Term: Rheumatoid arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Rheumatoid arthritis MedDRA version: 16.1;Level: PT;Classification code 10039073;Term: Rheumatoid ar ... | Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: SECUKINUMAB Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: SECUKINUMAB Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: SECUKINUMAB Product Name: Secukinum ... | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 234 | Phase 3 | United States;Portugal;Panama;Ecuador;Greece;Guatemala;Colombia;Italy;India;Czech Republic;Argentina;Brazil;Dominican Republic;South Africa;Germany;Japan;Korea, Republic of United States;Portugal;Panama;Ecuador;Greece;Guatemala;Colombia;Italy;India;Czech Republic;Argentina ... | ||
| 6 | EUCTR2012-002760-27-BG (EUCTR) | 21/01/201320130121 | 09/11/201220121109 | Extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in patients with active rheumatoid arthritis Extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in patien ... | A four year extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in patients with active rheumatoid arthritis A four year extension study to evaluate the long term efficacy, safety and tolerability of secukinum ... | Rheumatoid arthritis MedDRA version: 17.0;Level: PT;Classification code 10039073;Term: Rheumatoid arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Rheumatoid arthritis MedDRA version: 17.0;Level: PT;Classification code 10039073;Term: Rheumatoid ar ... | Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: SECUKINUMAB Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: SECUKINUMAB Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: SECUKINUMAB Product Name: Secukinum ... | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 345 | United States;Slovakia;Spain;Russian Federation;Colombia;Italy;France;Czech Republic;Hungary;Mexico;Canada;Brazil;Romania;Bulgaria;Germany United States;Slovakia;Spain;Russian Federation;Colombia;Italy;France;Czech Republic;Hungary;Mexico; ... | |||
| 7 | EUCTR2011-006058-94-PT (EUCTR) | 11/12/201220121211 | 23/10/201220121023 | Secukinumab efficacy and safety study in patients with active Rheumatoid Arthritis (RA) and an Inadequate response to anti-TNFa agents Secukinumab efficacy and safety study in patients with active Rheumatoid Arthritis (RA) and an Inade ... | A Phase III randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab in prefilled syringes to demonstrate the efficacy at 24 weeks and to assess the long term efficacy, safety, tolerability and usability up to 5 years in patients with active rheumatoid arthritis who have an inadequate response to anti-TNFa agents - REASSURE 2 A Phase III randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinum ... | Rheumatoid arthritis MedDRA version: 19.0;Level: PT;Classification code 10039073;Term: Rheumatoid arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Rheumatoid arthritis MedDRA version: 19.0;Level: PT;Classification code 10039073;Term: Rheumatoid ar ... | Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: SECUKINUMAB Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: SECUKINUMAB Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: SECUKINUMAB Product Name: Secukinum ... | Novartis Pharma AG | NULL | Not Recruiting | Female: yes Male: yes | 234 | Phase 3 | Panama;Portugal;United States;Ecuador;Greece;Guatemala;Colombia;Italy;India;Czech Republic;Argentina;Brazil;Dominican Republic;South Africa;Germany;Japan;Korea, Republic of Panama;Portugal;United States;Ecuador;Greece;Guatemala;Colombia;Italy;India;Czech Republic;Argentina ... | ||
| 8 | EUCTR2011-006058-94-GR (EUCTR) | 04/12/201220121204 | 23/10/201220121023 | Secukinumab efficacy and safety study in patients with active Rheumatoid Arthritis (RA) and an Inadequate response to anti-TNFa agents Secukinumab efficacy and safety study in patients with active Rheumatoid Arthritis (RA) and an Inade ... | A Phase III randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab in prefilled syringes to demonstrate the efficacy at 24 weeks and to assess the long term efficacy, safety, tolerability and usability up to 5 years in patients with active rheumatoid arthritis who have an inadequate response to anti-TNFa agents A Phase III randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinum ... | Rheumatoid arthritis MedDRA version: 14.1;Level: PT;Classification code 10039073;Term: Rheumatoid arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Rheumatoid arthritis MedDRA version: 14.1;Level: PT;Classification code 10039073;Term: Rheumatoid ar ... | Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: SECUKINUMAB Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: SECUKINUMAB Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: SECUKINUMAB Product Name: Secukinum ... | Novartis Pharma AG | NULL | Not Recruiting | Female: yes Male: yes | 234 | Phase 3 | Panama;Portugal;United States;Greece;Ecuador;Guatemala;Colombia;Italy;India;Czech Republic;Argentina;Brazil;Dominican Republic;South Africa;Germany;Korea, Republic of Panama;Portugal;United States;Greece;Ecuador;Guatemala;Colombia;Italy;India;Czech Republic;Argentina ... | ||
| 9 | EUCTR2012-002760-27-ES (EUCTR) | 14/11/201220121114 | 23/01/201320130123 | Extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in patients with active rheumatoid arthritis Extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in patien ... | A four year extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in patients with active rheumatoid arthritis A four year extension study to evaluate the long term efficacy, safety and tolerability of secukinum ... | Rheumatoid arthritis MedDRA version: 14.1;Level: PT;Classification code 10039073;Term: Rheumatoid arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Rheumatoid arthritis MedDRA version: 14.1;Level: PT;Classification code 10039073;Term: Rheumatoid ar ... | Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: SECUKINUMAB Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: SECUKINUMAB Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: SECUKINUMAB Product Name: Secukinum ... | Novartis Farmaceutica, S.A. | NULL | Not Recruiting | Female: yes Male: yes | 345 | United States;Slovakia;Spain;Russian Federation;Colombia;Italy;France;Czech Republic;Hungary;Mexico;Canada;Brazil;Romania;Bulgaria;Germany United States;Slovakia;Spain;Russian Federation;Colombia;Italy;France;Czech Republic;Hungary;Mexico; ... | |||
| 10 | EUCTR2012-002760-27-SK (EUCTR) | 12/11/201220121112 | 11/10/201220121011 | Extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in patients with active rheumatoid arthritis Extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in patien ... | A four year extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in patients with active rheumatoid arthritis A four year extension study to evaluate the long term efficacy, safety and tolerability of secukinum ... | Rheumatoid arthritis MedDRA version: 15.0;Level: PT;Classification code 10039073;Term: Rheumatoid arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Rheumatoid arthritis MedDRA version: 15.0;Level: PT;Classification code 10039073;Term: Rheumatoid ar ... | Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: SECUKINUMAB Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: SECUKINUMAB Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: SECUKINUMAB Product Name: Secukinum ... | Novartis Pharma AG | NULL | Not Recruiting | Female: yes Male: yes | 345 | United States;Slovakia;Spain;Russian Federation;Colombia;Italy;France;Czech Republic;Hungary;Mexico;Canada;Brazil;Romania;Bulgaria;Germany United States;Slovakia;Spain;Russian Federation;Colombia;Italy;France;Czech Republic;Hungary;Mexico; ... |
56. ベーチェット病
臨床試験数 : 81 / 薬物数 : 107 - (DrugBank : 30) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 116
Showing 1 to 10 of 12 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2009-013901-33-DE (EUCTR) | 21/06/201020100621 | 03/03/201020100303 | A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy (SHIELD Study) - C2303E1, SHIELD Study A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to ... | A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy (SHIELD Study) - C2303E1, SHIELD Study A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to ... | Adjunctive therapy to standard-of-care for the treatment of posterior uveitis or panuveitis secondary to Behçet's disease MedDRA version: 12.0;Level: LLT;Classification code 10036370;Term: Posterior uveitis Adjunctive therapy to standard-of-care for the treatment of posterior uveitis or panuveitis secondar ... | Product Name: AIN457 Product Code: AIN457 | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 112 | France;Greece;Spain;Austria;Germany | |||
| 2 | EUCTR2009-013901-33-GR (EUCTR) | 15/06/201020100615 | 22/02/201120110222 | A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy - C2303E1 A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to ... | A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy - C2303E1 A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to ... | Adjunctive therapy to standard-of-care for the treatment of posterior uveitis or panuveitis secondary to Behçet's disease MedDRA version: 12.0;Level: LLT;Classification code 10036370;Term: Posterior uveitis Adjunctive therapy to standard-of-care for the treatment of posterior uveitis or panuveitis secondar ... | Product Name: AIN457 Product Code: AIN457 | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 102 | Germany;France;Spain;Greece;Austria | |||
| 3 | EUCTR2009-013901-33-FR (EUCTR) | 07/04/201020100407 | 16/02/201020100216 | A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to ... | A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to ... | Adjunctive therapy to standard-of-care for the treatment of intermediate uveitis, posterior uveitis or panuveitis secondary to Behçet's disease MedDRA version: 12.0;Level: LLT;Classification code 10036370;Term: Posterior uveitis MedDRA version: 12.1;Classification code 10022557;Term: Intermediate uveitis MedDRA version: 12.1;Classification code 10033687;Term: Panuveitis Adjunctive therapy to standard-of-care for the treatment of intermediate uveitis, posterior uveitis ... | Product Name: AIN457 Product Code: AIN457 | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 146 | France;Greece;Spain;Austria;Germany | |||
| 4 | EUCTR2009-013901-33-ES (EUCTR) | 18/02/201020100218 | 18/01/201020100118 | Extensión de 38 semanas del estudio aleatorizado multicéntrico con doble enmascaramiento y controlado con placebo de 24 semanas de duración con el objetivo de evaluar la diferencia en el índice de recurrencia de exacerbaciones en pacientes con uveítis posterior o panuveítis secundaria a Behçet tratados con AIN457 o placebo de forma aditiva al tratamiento inmunosupresor de base - C2303E1 Extensión de 38 semanas del estudio aleatorizado multicéntrico con doble enmascaramiento y controlad ... | Extensión de 38 semanas del estudio aleatorizado multicéntrico con doble enmascaramiento y controlado con placebo de 24 semanas de duración con el objetivo de evaluar la diferencia en el índice de recurrencia de exacerbaciones en pacientes con uveítis posterior o panuveítis secundaria a Behçet tratados con AIN457 o placebo de forma aditiva al tratamiento inmunosupresor de base - C2303E1 Extensión de 38 semanas del estudio aleatorizado multicéntrico con doble enmascaramiento y controlad ... | terapia adyuvante de los agentes inmunosupresores de base para el tratamiento de la uveítis posterior o de la panuveítis secundaria a la enfermedad de Behçet MedDRA version: 9;Level: LLT;Classification code 10004212;Term: Behcet's disease terapia adyuvante de los agentes inmunosupresores de base para el tratamiento de la uveítis posterio ... | Product Name: AIN457 Product Code: AIN457 INN or Proposed INN: AIN457 | Novartis Farmacéutica, S.A. | NULL | Not Recruiting | Female: yes Male: yes | 159 | Germany;France;Spain;Greece;Austria | |||
| 5 | EUCTR2009-011237-27-DE (EUCTR) | 17/11/200920091117 | 06/08/200920090806 | A 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy (SHIELD Study) - C2303 A 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference ... | A 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy (SHIELD Study) - C2303 A 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference ... | Adjunctive therapy to standard-of-care for the treatment of posterior uveitis or panuveitis secondary to Behçet's disease Adjunctive therapy to standard-of-care for the treatment of posterior uveitis or panuveitis secondar ... | Product Name: AIN457 Product Code: AIN457 | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 112 | Hungary;Germany;France;Spain;Italy;Greece;Austria | |||
| 6 | EUCTR2009-013901-33-AT (EUCTR) | 12/11/200920091112 | 13/10/200920091013 | A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy - C2303E1 A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to ... | A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy - C2303E1 A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to ... | Adjunctive therapy to standard-of-care for the treatment of posterior uveitis or panuveitis secondary to Behçet's disease MedDRA version: 12.0;Level: LLT;Classification code 10036370;Term: Posterior uveitis Adjunctive therapy to standard-of-care for the treatment of posterior uveitis or panuveitis secondar ... | Product Name: AIN457 Product Code: AIN457 | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 112 | Germany;France;Spain;Greece;Austria | |||
| 7 | EUCTR2009-011237-27-FR (EUCTR) | 23/10/200920091023 | 06/08/200920090806 | A 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy A 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference ... | A 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy A 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference ... | Adjunctive therapy to standard-of-care for the treatment of posterior uveitis or panuveitis secondary to Behçet's disease MedDRA version: 12.0;Level: LLT;Classification code 10033687;Term: Panuveitis MedDRA version: 12.0;Classification code 10036370;Term: Posterior uveitis Adjunctive therapy to standard-of-care for the treatment of posterior uveitis or panuveitis secondar ... | Product Name: AIN457 Product Code: AIN457 INN or Proposed INN: Not available Other descriptive name: rhumAb to Il-17A (IgG1-k-class) Product Name: AIN457 Product Code: AIN457 INN or Proposed INN: Not available Other descriptive name: rh ... | Novartis Pharma Services Ag | NULL | Not Recruiting | Female: yes Male: yes | 102 | France;Hungary;Greece;Spain;Austria;Germany;Italy | |||
| 8 | EUCTR2009-011237-27-ES (EUCTR) | 20/10/200920091020 | 05/08/200920090805 | Estudio aleatorizado multicéntrico, con doble enmascaramiento y controlado con placebo de 24 semanas de duración con el objetivo de evaluar la diferencia en el índice de recurrencia de exacerbaciones en pacientes con uveitis posterior o panuveitis secundaria a Behçet tratados con AIN457 o placebo de forma aditiva al tratamiento inmunosupresor de base. - C2303 Estudio aleatorizado multicéntrico, con doble enmascaramiento y controlado con placebo de 24 semanas ... | Estudio aleatorizado multicéntrico, con doble enmascaramiento y controlado con placebo de 24 semanas de duración con el objetivo de evaluar la diferencia en el índice de recurrencia de exacerbaciones en pacientes con uveitis posterior o panuveitis secundaria a Behçet tratados con AIN457 o placebo de forma aditiva al tratamiento inmunosupresor de base. - C2303 Estudio aleatorizado multicéntrico, con doble enmascaramiento y controlado con placebo de 24 semanas ... | Tratamiento de uveítis posterior o panuveítis secundaria a Behçet de forma aditiva al tratamiento inmunosupresor de base MedDRA version: 9;Level: LLT;Classification code 10004212;Term: Behcet's disease Tratamiento de uveítis posterior o panuveítis secundaria a Behçet de forma aditiva al tratamiento in ... | Product Name: AIN457 Product Code: AIN457 INN or Proposed INN: AIN457 | Novartis Farmacéutica, S.A. | NULL | Not Recruiting | Female: yes Male: yes | 102 | Phase 3 | France;Hungary;Greece;Spain;Austria;Germany;Italy | ||
| 9 | EUCTR2009-011237-27-HU (EUCTR) | 15/10/200920091015 | 29/07/200920090729 | A 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy - C2303 A 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference ... | A 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy - C2303 A 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference ... | Adjunctive therapy to standard-of-care for the treatment of posterior uveitis or panuveitis secondary to Behçet's disease MedDRA version: 12.0;Level: LLT;Classification code 10036370;Term: Posterior uveitis Adjunctive therapy to standard-of-care for the treatment of posterior uveitis or panuveitis secondar ... | Product Name: AIN457 Product Code: AIN457 | Novartis Pharma Services Ag | NULL | Not Recruiting | Female: yes Male: yes | 112 | France;Hungary;Greece;Spain;Austria;Germany;Italy | |||
| 10 | EUCTR2009-011237-27-AT (EUCTR) | 14/10/200920091014 | 18/09/200920090918 | A 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy - C2303 A 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference ... | A 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy - C2303 A 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference ... | Adjunctive therapy to standard-of-care for the treatment of posterior uveitis or panuveitis secondary to Behçet's disease Adjunctive therapy to standard-of-care for the treatment of posterior uveitis or panuveitis secondar ... | Product Name: AIN457 Product Code: AIN457 | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 112 | Hungary;Germany;France;Spain;Italy;Greece;Austria |
96. クローン病
臨床試験数 : 2,442 / 薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209
Showing 1 to 7 of 7 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2009-011621-14-DE (EUCTR) | 12/05/201020100512 | 26/01/201020100126 | A 52-week open label extension study to evaluate the safety and tolerability of AIN457 (anti IL-17 monoclonal antibody) in patients with moderate to severe Crohn’sdisease - n/a A 52-week open label extension study to evaluate the safety and tolerability of AIN457(anti IL-17 mo ... | A 52-week open label extension study to evaluate the safety and tolerability of AIN457 (anti IL-17 monoclonal antibody) in patients with moderate to severe Crohn’sdisease - n/a A 52-week open label extension study to evaluate the safety and tolerability of AIN457(anti IL-17 mo ... | Moderate to severe Crohn's disease (CDAI = 220 and =450) MedDRA version: 9.1;Level: LLT;Classification code 10011401;Term: Crohn's disease Moderate to severe Crohn's disease (CDAI = 220 and =450) MedDRA version: 9.1;Level: LLT;Classificati ... | Product Name: AIN457 Product Code: AIN457 | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 72 | Germany;Austria | |||
| 2 | EUCTR2009-011621-14-AT (EUCTR) | 12/11/200920091112 | 19/10/200920091019 | A 52-week open label extension study to evaluate the safety and tolerability of AIN457 (anti IL-17 monoclonal antibody) in patients with moderate to severe Crohn’sdisease - A2202E1 A 52-week open label extension study to evaluate the safety and tolerability of AIN457(anti IL-17 mo ... | A 52-week open label extension study to evaluate the safety and tolerability of AIN457 (anti IL-17 monoclonal antibody) in patients with moderate to severe Crohn’sdisease - A2202E1 A 52-week open label extension study to evaluate the safety and tolerability of AIN457(anti IL-17 mo ... | Moderate to severe Crohn's disease (CDAI = 220 and =450) MedDRA version: 9.1;Level: LLT;Classification code 10011401;Term: Crohn's disease Moderate to severe Crohn's disease (CDAI = 220 and =450) MedDRA version: 9.1;Level: LLT;Classificati ... | Product Name: AIN457 Product Code: AIN457 INN or Proposed INN: Not available Other descriptive name: None Product Name: AIN457 Product Code: AIN457 INN or Proposed INN: Not available Other descriptive name: No ... | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 72 | Germany;Austria | |||
| 3 | NCT01009281 (ClinicalTrials.gov) | October 200920091000 | 5/11/200920091105 | An Open Label Safety and Tolerability Study of AIN457 in Patients With Moderate to Severe Crohn's Disease An Open Label Safety and Tolerability Study of AIN457in Patients With Moderate to Severe Crohn's Dis ... | A 52 Week Open Label Extension Study to Evaluate the Safety and Tolerability of AIN457 (Anti IL-17 Monoclonal Antibody) in Patients With Moderate to Severe Crohn's Disease A 52 Week Open Label Extension Study to Evaluate the Safety and Tolerability of AIN457(Anti IL-17 Mo ... | Crohn's Disease;Inflammatory Bowel Disease | Drug: AIN457 | Novartis Pharmaceuticals | NULL | Terminated | 18 Years | 75 Years | All | 7 | Phase 2 | United States;Austria;Canada;Germany;Poland |
| 4 | EUCTR2008-008359-40-DE (EUCTR) | 08/09/200920090908 | 23/06/200920090623 | A multicenter, randomised, double-blind, placebo-controlled, parallel-group proof-of-concept study to assess the efficacy, safety and tolerability of two single i.v. infusions of AIN457 10 mg/kg (anti IL-17 monoclonal antibody) in patients with moderate to severe active Crohn's disease - A2202 A multicenter, randomised, double-blind, placebo-controlled, parallel-group proof-of-concept study t ... | A multicenter, randomised, double-blind, placebo-controlled, parallel-group proof-of-concept study to assess the efficacy, safety and tolerability of two single i.v. infusions of AIN457 10 mg/kg (anti IL-17 monoclonal antibody) in patients with moderate to severe active Crohn's disease - A2202 A multicenter, randomised, double-blind, placebo-controlled, parallel-group proof-of-concept study t ... | Moderate to severe Crohn's disease (CDAI >/= 220 and MedDRA version: 9.1;Level: LLT;Classification code 10011401;Term: Crohn's disease Moderate to severe Crohn's disease (CDAI >/= 220 and MedDRA version: 9.1;Level: LLT;Classification c ... | Product Name: AIN457 Product Code: AIN457 INN or Proposed INN: not available Other descriptive name: rhumAb to Il-17A (IgG1-k-class) Product Name: AIN457 Product Code: AIN457 INN or Proposed INN: not available Other descriptive name: rh ... | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 72 | Germany;Poland;Austria | |||
| 5 | EUCTR2008-008359-40-PL (EUCTR) | 02/09/200920090902 | 07/04/200920090407 | A multicenter, randomised, double-blind, placebo-controlled, parallel-group proof- of-concept study to assess the efficacy, safety and tolerability of two single i.v. infusions of AIN457 10 mg/kg (anti-IL17 monoclonal antibody) in patients with moderate to severe active Crohn’s disease - A2202 A multicenter, randomised, double-blind, placebo-controlled, parallel-group proof- of-concept study ... | A multicenter, randomised, double-blind, placebo-controlled, parallel-group proof- of-concept study to assess the efficacy, safety and tolerability of two single i.v. infusions of AIN457 10 mg/kg (anti-IL17 monoclonal antibody) in patients with moderate to severe active Crohn’s disease - A2202 A multicenter, randomised, double-blind, placebo-controlled, parallel-group proof- of-concept study ... | Moderate to severe Crohn's disease (CDAI = 220 and =450) MedDRA version: 9.1;Level: LLT;Classification code 10011401;Term: Crohn's disease Moderate to severe Crohn's disease (CDAI = 220 and =450) MedDRA version: 9.1;Level: LLT;Classificati ... | Product Name: AIN457 Product Code: AIN457 Other descriptive name: rhumAb to Il-17A (IgG1-k-class) rhumAb to Il-17A (IgG1-k-class) Product Name: AIN457 Product Code: AIN457 Other descriptive name: rhumAb to Il-17A (IgG1-k-class) rhum ... | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 72 | Germany;Austria;Poland | |||
| 6 | EUCTR2008-008359-40-AT (EUCTR) | 07/05/200920090507 | 31/03/200920090331 | A multicenter, randomised, double-blind, placebo-controlled, parallel-group proof- of-concept study to assess the efficacy, safety and tolerability of two single i.v. infusions of AIN457 10 mg/kg (anti-IL17 monoclonal antibody) in patients with moderate to severe active Crohn’s disease - A2202 A multicenter, randomised, double-blind, placebo-controlled, parallel-group proof- of-concept study ... | A multicenter, randomised, double-blind, placebo-controlled, parallel-group proof- of-concept study to assess the efficacy, safety and tolerability of two single i.v. infusions of AIN457 10 mg/kg (anti-IL17 monoclonal antibody) in patients with moderate to severe active Crohn’s disease - A2202 A multicenter, randomised, double-blind, placebo-controlled, parallel-group proof- of-concept study ... | Moderate to severe Crohn's disease (CDAI = 220 and =450) MedDRA version: 9.1;Level: LLT;Classification code 10011401;Term: Crohn's disease Moderate to severe Crohn's disease (CDAI = 220 and =450) MedDRA version: 9.1;Level: LLT;Classificati ... | Product Name: AIN457 Product Code: AIN457 | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 72 | Germany;Poland;Austria | |||
| 7 | NCT00584740 (ClinicalTrials.gov) | August 200820080800 | 21/12/200720071221 | Efficacy, Safety and Tolerability of AIN457 in Moderate to Severe Active Crohn's Disease | A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Proof-of-concept Study to Assess the Efficacy, Safety and Tolerability of Two Single iv Infusions of AIN457 10 mg/kg (Anti IL-17 Monoclonal Antibody) in Patients With Moderate to Severe Active Crohn's Disease A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Proof-of-concept Study t ... | Crohn's Disease | Drug: AIN457;Drug: Placebo | Novartis Pharmaceuticals | NULL | Terminated | 18 Years | 75 Years | All | 59 | Phase 2 | Germany;Canada;United States |
107. 若年性特発性関節炎
臨床試験数 : 447 / 薬物数 : 297 - (DrugBank : 57) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 146
Showing 1 to 10 of 11 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2018-002521-30-DE (EUCTR) | 09/05/201920190509 | 08/01/201920190108 | An extension study of subcutaneous secukinumab in patients with Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA) An extension study of subcutaneous secukinumab in patients with Juvenile Psoriatic Arthritis (JPsA) ... | An extension study of subcutaneous secukinumab to evaluate the long-term efficacy, safety and tolerability up to 4 years in patients with Juvenile Idiopathic Arthritis subtypes of Juvenile Psoriatic Arthritis and Enthesitis Related Arthritis An extension study of subcutaneous secukinumab to evaluate the long-term efficacy, safety and tolera ... | Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis MedDRA version: 20.0;Level: LLT;Classification code 10072745;Term: Enthesitis related arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 20.0;Level: PT;Classification code 10076674;Term: Juvenile psoriatic arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis MedDRA version: 20.0;Level: LLT;Classi ... | Trade Name: COSENTYX INN or Proposed INN: Secukinumab Other descriptive name: SECUKINUMAB Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: Secukinumab Other descriptive name: SECUKINUMAB Trade Name: COSENTYX INN or Proposed INN: Secukinumab Other descriptive name: SECUKINUMAB Product Name: ... | Novartis Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 63 | Phase 3 | United States;Spain;Poland;Belgium;Turkey;South Africa;Russian Federation;Germany;Italy | ||
| 2 | EUCTR2018-002521-30-IT (EUCTR) | 16/04/201920190416 | 15/06/202120210615 | An extension study of subcutaneous secukinumab in patients with Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA) An extension study of subcutaneous secukinumab in patients with Juvenile Psoriatic Arthritis (JPsA) ... | An extension study of subcutaneous secukinumab to evaluate the long-term efficacy, safety and tolerability up to 4 years in patients with Juvenile Idiopathic Arthritis subtypes of Juvenile Psoriatic Arthritis and Enthesitis Related Arthritis - Secukinumab long-term safety, tolerability and efficacy in JPsA and ERA up to 4 years An extension study of subcutaneous secukinumab to evaluate the long-term efficacy, safety and tolera ... | Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis MedDRA version: 20.0;Level: LLT;Classification code 10072745;Term: Enthesitis related arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 20.0;Level: PT;Classification code 10076674;Term: Juvenile psoriatic arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis MedDRA version: 20.0;Level: LLT;Classi ... | Trade Name: COSENTYX - 150 MG - SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA -USO SOTTOCUTANEO - SIRINGA (VETRO) 1 ML (150MG/ML)- 2 SIRINGHE PRERIEMPITE Product Name: - Product Code: [-] INN or Proposed INN: Secukinumab Other descriptive name: SECUKINUMAB Product Name: Secukinumab Product Code: [AIN457] INN or Proposed INN: Secukinumab Other descriptive name: SECUKINUMAB Trade Name: COSENTYX - 150 MG - SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA -USO SOTTOCUTANEO - SIR ... | NOVARTIS PHARMA AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 63 | Phase 3 | United States;Spain;Poland;Belgium;Turkey;South Africa;Russian Federation;Germany;Italy | ||
| 3 | EUCTR2018-002521-30-ES (EUCTR) | 15/03/201920190315 | 27/03/201920190327 | An extension study of subcutaneous secukinumab in patients with Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA) An extension study of subcutaneous secukinumab in patients with Juvenile Psoriatic Arthritis (JPsA) ... | An extension study of subcutaneous secukinumab to evaluate the long-term efficacy, safety and tolerability up to 4 years in patients with Juvenile Idiopathic Arthritis subtypes of Juvenile Psoriatic Arthritis and Enthesitis Related Arthritis An extension study of subcutaneous secukinumab to evaluate the long-term efficacy, safety and tolera ... | Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis MedDRA version: 20.0;Level: LLT;Classification code 10072745;Term: Enthesitis related arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 20.0;Level: PT;Classification code 10076674;Term: Juvenile psoriatic arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis MedDRA version: 20.0;Level: LLT;Classi ... | Trade Name: COSENTYX INN or Proposed INN: Secukinumab Other descriptive name: SECUKINUMAB Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: Secukinumab Other descriptive name: SECUKINUMAB Trade Name: COSENTYX INN or Proposed INN: Secukinumab Other descriptive name: SECUKINUMAB Product Name: ... | Novartis Farmacéutica, S.A. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 63 | Phase 3 | United States;Poland;Belgium;Spain;Turkey;Russian Federation;South Africa;Germany;Italy | ||
| 4 | EUCTR2016-003761-26-PL (EUCTR) | 30/06/201720170630 | 24/05/201720170524 | Secukinumab safety and efficacy in JPsA and ERA | A three-part randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of secukinumab treatment in Juvenile Idiopathic arthritis subtypes of psoriatic and enthesitis-related arthritis A three-part randomized, double-blind, placebo-controlled study to investigate the efficacy and safe ... | Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis MedDRA version: 20.0;Level: LLT;Classification code 10072745;Term: Enthesitis related arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 20.0;Level: PT;Classification code 10076674;Term: Juvenile psoriatic arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis MedDRA version: 20.0;Level: LLT;Classi ... | Trade Name: COSENTYX INN or Proposed INN: Secukinumab Other descriptive name: SECUKINUMAB Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: Secukinumab Other descriptive name: SECUKINUMAB Trade Name: COSENTYX INN or Proposed INN: Secukinumab Other descriptive name: SECUKINUMAB Product Name: ... | Novartis Pharma AG | NULL | Not Recruiting | Female: yes Male: yes | 80 | Phase 3 | United States;Spain;Belgium;Poland;Turkey;South Africa;Russian Federation;Germany;United Kingdom;Italy United States;Spain;Belgium;Poland;Turkey;South Africa;Russian Federation;Germany;United Kingdom;Ita ... | ||
| 5 | EUCTR2016-003761-26-BE (EUCTR) | 15/06/201720170615 | 16/03/201720170316 | Secukinumab safety and efficacy in JPsA and ERA | A three-part randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of secukinumab treatment in Juvenile Idiopathic arthritis subtypes of psoriatic and enthesitis-related arthritis A three-part randomized, double-blind, placebo-controlled study to investigate the efficacy and safe ... | Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis MedDRA version: 20.0;Level: LLT;Classification code 10072745;Term: Enthesitis related arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 20.0;Level: PT;Classification code 10076674;Term: Juvenile psoriatic arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis MedDRA version: 20.0;Level: LLT;Classi ... | Trade Name: COSENTYX INN or Proposed INN: Secukinumab Other descriptive name: SECUKINUMAB Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: Secukinumab Other descriptive name: SECUKINUMAB Trade Name: COSENTYX INN or Proposed INN: Secukinumab Other descriptive name: SECUKINUMAB Product Name: ... | Novartis Pharma AG | NULL | Not Recruiting | Female: yes Male: yes | 80 | Phase 3 | United States;Spain;Poland;Belgium;Turkey;South Africa;Russian Federation;Germany;United Kingdom;Italy United States;Spain;Poland;Belgium;Turkey;South Africa;Russian Federation;Germany;United Kingdom;Ita ... | ||
| 6 | EUCTR2016-003761-26-GB (EUCTR) | 10/03/201720170310 | 13/12/201620161213 | Secukinumab safety and efficacy in JPsA and ERA | A three-part randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of secukinumab treatment in Juvenile Idiopathic arthritis subtypes of psoriatic and enthesitis-related arthritis A three-part randomized, double-blind, placebo-controlled study to investigate the efficacy and safe ... | Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis MedDRA version: 20.0;Level: LLT;Classification code 10072745;Term: Enthesitis related arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 20.0;Level: PT;Classification code 10076674;Term: Juvenile psoriatic arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis MedDRA version: 20.0;Level: LLT;Classi ... | Trade Name: COSENTYX INN or Proposed INN: Secukinumab Other descriptive name: SECUKINUMAB Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: Secukinumab Other descriptive name: SECUKINUMAB Trade Name: COSENTYX INN or Proposed INN: Secukinumab Other descriptive name: SECUKINUMAB Product Name: ... | Novartis Pharma AG | NULL | Not Recruiting | Female: yes Male: yes | 80 | Phase 3 | United States;Spain;Poland;Belgium;Turkey;South Africa;Russian Federation;Germany;Italy;United Kingdom United States;Spain;Poland;Belgium;Turkey;South Africa;Russian Federation;Germany;Italy;United Kingd ... | ||
| 7 | EUCTR2016-003761-26-ES (EUCTR) | 01/03/201720170301 | 15/12/201620161215 | Secukinumab safety and efficacy in JPsA and ERA | A three-part randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of secukinumab treatment in Juvenile Idiopathic arthritis subtypes of psoriatic and enthesitis-related arthritis A three-part randomized, double-blind, placebo-controlled study to investigate the efficacy and safe ... | Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis MedDRA version: 19.0;Level: LLT;Classification code 10072745;Term: Enthesitis related arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 19.0;Level: PT;Classification code 10076674;Term: Juvenile psoriatic arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis MedDRA version: 19.0;Level: LLT;Classi ... | Trade Name: COSENTYX INN or Proposed INN: Secukinumab Other descriptive name: SECUKINUMAB Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: Secukinumab Other descriptive name: SECUKINUMAB Trade Name: COSENTYX INN or Proposed INN: Secukinumab Other descriptive name: SECUKINUMAB Product Name: ... | Novartis Farmacéutica S.A. | NULL | Not Recruiting | Female: yes Male: yes | 80 | Phase 3 | United States;Poland;Belgium;Spain;Turkey;South Africa;Russian Federation;Netherlands;Germany;United Kingdom;Italy United States;Poland;Belgium;Spain;Turkey;South Africa;Russian Federation;Netherlands;Germany;United ... | ||
| 8 | EUCTR2016-003761-26-DE (EUCTR) | 06/02/201720170206 | 12/12/201620161212 | Secukinumab safety and efficacy in JPsA and ERA | A three-part randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of secukinumab treatment in Juvenile Idiopathic arthritis subtypes of psoriatic and enthesitis-related arthritis A three-part randomized, double-blind, placebo-controlled study to investigate the efficacy and safe ... | Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis MedDRA version: 20.0;Level: LLT;Classification code 10072745;Term: Enthesitis related arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 20.0;Level: PT;Classification code 10076674;Term: Juvenile psoriatic arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis MedDRA version: 20.0;Level: LLT;Classi ... | Trade Name: COSENTYX INN or Proposed INN: Secukinumab Other descriptive name: SECUKINUMAB Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: Secukinumab Other descriptive name: SECUKINUMAB Trade Name: COSENTYX INN or Proposed INN: Secukinumab Other descriptive name: SECUKINUMAB Product Name: ... | Novartis Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 80 | Phase 3 | United States;Poland;Belgium;Spain;Turkey;Russian Federation;South Africa;Germany;Italy;United Kingdom United States;Poland;Belgium;Spain;Turkey;Russian Federation;South Africa;Germany;Italy;United Kingd ... | ||
| 9 | EUCTR2016-003761-26-IT (EUCTR) | 00000000 | 10/11/202020201110 | Secukinumab safety and efficacy in JPsA and ERA | A three-part randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of secukinumab treatment in Juvenile Idiopathic arthritis subtypes of psoriatic and enthesitis-related arthritis - Secukinumab safety and efficacy in JPsA and ERA A three-part randomized, double-blind, placebo-controlled study to investigate the efficacy and safe ... | Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis MedDRA version: 20.0;Level: PT;Classification code 10076674;Term: Juvenile psoriatic arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 20.0;Level: LLT;Classification code 10072745;Term: Enthesitis related arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis MedDRA version: 20.0;Level: PT;Classif ... | Trade Name: COSENTYX - 150 MG - SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA -USO SOTTOCUTANEO - SIRINGA (VETRO) 1 ML (150MG/ML)- 1 SIRINGA PRERIEMPITA Product Name: NA Product Code: AIN457F INN or Proposed INN: SECUKINUMAB Other descriptive name: SECUKINUMAB Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: Secukinumab Other descriptive name: SECUKINUMAB Trade Name: COSENTYX - 150 MG - SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA -USO SOTTOCUTANEO - SIR ... | NOVARTIS PHARMA AG | NULL | Not Recruiting | Female: yes Male: yes | 80 | Phase 3 | United States;Spain;Poland;Belgium;Turkey;Netherlands;Germany;United Kingdom;Italy | ||
| 10 | EUCTR2018-002521-30-BE (EUCTR) | 00000000 | 09/07/201920190709 | An extension study of subcutaneous secukinumab in patients with Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA) An extension study of subcutaneous secukinumab in patients with Juvenile Psoriatic Arthritis (JPsA) ... | An extension study of subcutaneous secukinumab to evaluate the long-term efficacy, safety and tolerability up to 4 years in patients with Juvenile Idiopathic Arthritis subtypes of Juvenile Psoriatic Arthritis and Enthesitis Related Arthritis An extension study of subcutaneous secukinumab to evaluate the long-term efficacy, safety and tolera ... | Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis MedDRA version: 20.0;Level: LLT;Classification code 10072745;Term: Enthesitis related arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 20.0;Level: PT;Classification code 10076674;Term: Juvenile psoriatic arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis MedDRA version: 20.0;Level: LLT;Classi ... | Trade Name: COSENTYX INN or Proposed INN: Secukinumab Other descriptive name: SECUKINUMAB Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: Secukinumab Other descriptive name: SECUKINUMAB Trade Name: COSENTYX INN or Proposed INN: Secukinumab Other descriptive name: SECUKINUMAB Product Name: ... | Novartis Pharma AG | NULL | NA | Female: yes Male: yes | 63 | Phase 3 | United States;Spain;Poland;Belgium;Turkey;South Africa;Russian Federation;Germany;Italy |
271. 強直性脊椎炎
臨床試験数 : 574 / 薬物数 : 359 - (DrugBank : 68) / 標的遺伝子数 : 41 - 標的パスウェイ数 : 146
Showing 1 to 10 of 74 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2020-004284-98-GR (EUCTR) | 15/07/202120210715 | 05/04/202120210405 | Secukinumab open label roll-over extension protocol | An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the investigator to benefit from continued Secukinumab treatment An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored S ... | Psoriatic Arthritis, Ankylosing Spondylitis, non-radiographic axial spondyloarthritis, Severe Chronic Plaque Psoriasis MedDRA version: 21.0;Level: LLT;Classification code 10037160;Term: Psoriatic arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 20.0;Level: PT;Classification code 10002556;Term: Ankylosing spondylitis;Classification code 10076297;Term: Non-radiographic axial spondyloarthritis;Classification code 10050576;Term: Psoriasis vulgaris;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Psoriatic Arthritis, Ankylosing Spondylitis, non-radiographic axial spondyloarthritis, Severe Chroni ... | Trade Name: Cosentyx Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: secukinumab Other descriptive name: SECUKINUMAB Trade Name: Cosentyx Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: Secukinumab Other descriptive name: SECUKINUMAB Trade Name: Cosentyx Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: secukinumab Oth ... | Novartis Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 628 | Phase 4 | United States;Czechia;Greece;Spain;Guatemala;Russian Federation;Colombia;India;Egypt;Czech Republic;Mexico;Poland;Brazil;Malaysia;Belgium;Bulgaria;South Africa;Korea, Republic of United States;Czechia;Greece;Spain;Guatemala;Russian Federation;Colombia;India;Egypt;Czech Republic; ... | ||
| 2 | EUCTR2020-004284-98-BG (EUCTR) | 05/02/202120210205 | 29/01/202120210129 | Secukinumab open label roll-over extension protocol | An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the investigator to benefit from continued Secukinumab treatment An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored S ... | Psoriatic Arthritis, Ankylosing Spondylitis, non-radiographic axial spondyloarthritis, Severe Chronic Plaque Psoriasis MedDRA version: 21.0;Level: LLT;Classification code 10037160;Term: Psoriatic arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 20.0;Level: PT;Classification code 10002556;Term: Ankylosing spondylitis;Classification code 10076297;Term: Non-radiographic axial spondyloarthritis;Classification code 10050576;Term: Psoriasis vulgaris;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Psoriatic Arthritis, Ankylosing Spondylitis, non-radiographic axial spondyloarthritis, Severe Chroni ... | Trade Name: Cosentyx Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: secukinumab Other descriptive name: SECUKINUMAB Trade Name: Cosentyx Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: Secukinumab Trade Name: Cosentyx Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: secukinumab Oth ... | Novartis Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 628 | Phase 4 | United States;Czechia;Greece;Spain;Guatemala;Turkey;Russian Federation;Colombia;India;Egypt;Czech Republic;Mexico;Poland;Belgium;Brazil;Malaysia;Bulgaria;South Africa;Germany;Sweden;Korea, Republic of United States;Czechia;Greece;Spain;Guatemala;Turkey;Russian Federation;Colombia;India;Egypt;Czech Re ... | ||
| 3 | EUCTR2019-001177-90-SE (EUCTR) | 30/06/202020200630 | 17/12/201920191217 | Study to demonstrate the efficacy, safety and tolerability of an intravenous(i.v.) regimen of secukinumab compared to placebo in subjects with activeaxSpA Study to demonstrate the efficacy, safety and tolerability of an intravenous(i.v.) regimen of secuki ... | A randomized, double-blind, placebo-controlled, parallel group, phase IIImulticenter study of intravenous secukinumab to compare efficacy at 16weeks with placebo and to assess safety and tolerability up to 52 weeks insubjects with active Ankylosing Spondylitis or non-radiographic axialSpondyloArthritis A randomized, double-blind, placebo-controlled, parallel group, phase IIImulticenter study of intrav ... | Axial Spondyloarthritis MedDRA version: 21.1;Level: PT;Classification code 10071400;Term: Axial spondyloarthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Axial Spondyloarthritis MedDRA version: 21.1;Level: PT;Classification code 10071400;Term: Axial spon ... | Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: Secukinumab Other descriptive name: SECUKINUMAB Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: Secukinumab Other descriptive name: ... | Novartis Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 500 | Phase 3 | United States;Czechia;Philippines;Greece;Thailand;Guatemala;Turkey;Russian Federation;Colombia;Italy;India;Egypt;Poland;Belgium;Brazil;Malaysia;Bulgaria;Sweden;Korea, Republic of United States;Czechia;Philippines;Greece;Thailand;Guatemala;Turkey;Russian Federation;Colombia;Italy ... | ||
| 4 | EUCTR2019-001177-90-IT (EUCTR) | 06/05/202020200506 | 19/05/202120210519 | Study to demonstrate the efficacy, safety and tolerability of an intravenous(i.v.) regimen of secukinumab compared to placebo in subjects with activeaxSpA Study to demonstrate the efficacy, safety and tolerability of an intravenous(i.v.) regimen of secuki ... | A randomized, double-blind, placebo-controlled, parallel group, phase IIImulticenter study of intravenous secukinumab to compare efficacy at 16weeks with placebo and to assess safety and tolerability up to 52 weeks insubjects with active Ankylosing Spondylitis or non-radiographic axialSpondyloArthritis A randomized, double-blind, placebo-controlled, parallel group, phase IIImulticenter study of intrav ... | Axial Spondyloarthritis MedDRA version: 21.1;Level: PT;Classification code 10071400;Term: Axial spondyloarthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Axial Spondyloarthritis MedDRA version: 21.1;Level: PT;Classification code 10071400;Term: Axial spon ... | Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: Secukinumab Other descriptive name: SECUKINUMAB Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: Secukinumab Other descriptive name: ... | Novartis Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 500 | Phase 3 | United States;Czechia;Philippines;Greece;Thailand;Guatemala;Turkey;Russian Federation;Colombia;Italy;India;Egypt;Czech Republic;Poland;Belgium;Brazil;Malaysia;Bulgaria;Sweden;Korea, Republic of United States;Czechia;Philippines;Greece;Thailand;Guatemala;Turkey;Russian Federation;Colombia;Italy ... | ||
| 5 | EUCTR2019-001177-90-BG (EUCTR) | 07/04/202020200407 | 12/02/202020200212 | Study to demonstrate the efficacy, safety and tolerability of an intravenous(i.v.) regimen of secukinumab compared to placebo in subjects with activeaxSpA Study to demonstrate the efficacy, safety and tolerability of an intravenous(i.v.) regimen of secuki ... | A randomized, double-blind, placebo-controlled, parallel group, phase IIImulticenter study of intravenous secukinumab to compare efficacy at 16weeks with placebo and to assess safety and tolerability up to 52 weeks insubjects with active Ankylosing Spondylitis or non-radiographic axialSpondyloArthritis A randomized, double-blind, placebo-controlled, parallel group, phase IIImulticenter study of intrav ... | Axial Spondyloarthritis MedDRA version: 21.1;Level: PT;Classification code 10071400;Term: Axial spondyloarthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Axial Spondyloarthritis MedDRA version: 21.1;Level: PT;Classification code 10071400;Term: Axial spon ... | Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: Secukinumab Other descriptive name: SECUKINUMAB Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: Secukinumab Other descriptive name: ... | Novartis Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 500 | Phase 3 | United States;Philippines;Czechia;Greece;Thailand;Guatemala;Turkey;Russian Federation;Colombia;Italy;India;Egypt;Czech Republic;Poland;Malaysia;Belgium;Brazil;Bulgaria;Sweden;Korea, Republic of United States;Philippines;Czechia;Greece;Thailand;Guatemala;Turkey;Russian Federation;Colombia;Italy ... | ||
| 6 | EUCTR2019-001177-90-CZ (EUCTR) | 20/02/202020200220 | 19/12/201920191219 | Study to demonstrate the efficacy, safety and tolerability of an intravenous(i.v.) regimen of secukinumab compared to placebo in subjects with activeaxSpA Study to demonstrate the efficacy, safety and tolerability of an intravenous(i.v.) regimen of secuki ... | A randomized, double-blind, placebo-controlled, parallel group, phase IIImulticenter study of intravenous secukinumab to compare efficacy at 16weeks with placebo and to assess safety and tolerability up to 52 weeks insubjects with active Ankylosing Spondylitis or non-radiographic axialSpondyloArthritis A randomized, double-blind, placebo-controlled, parallel group, phase IIImulticenter study of intrav ... | Axial Spondyloarthritis MedDRA version: 21.1;Level: PT;Classification code 10071400;Term: Axial spondyloarthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Axial Spondyloarthritis MedDRA version: 21.1;Level: PT;Classification code 10071400;Term: Axial spon ... | Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: Secukinumab Other descriptive name: SECUKINUMAB Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: Secukinumab Other descriptive name: ... | Novartis Pharma AG | NULL | Not Recruiting | Female: yes Male: yes | 500 | Phase 3 | United States;Czechia;Philippines;Greece;Thailand;Guatemala;Turkey;Russian Federation;Colombia;Italy;India;Egypt;Czech Republic;Belgium;Brazil;Malaysia;Poland;Bulgaria;Korea, Republic of;Sweden United States;Czechia;Philippines;Greece;Thailand;Guatemala;Turkey;Russian Federation;Colombia;Italy ... | ||
| 7 | EUCTR2019-001177-90-GR (EUCTR) | 23/01/202020200123 | 13/11/201920191113 | Study to demonstrate the efficacy, safety and tolerability of an intravenous(i.v.) regimen of secukinumab compared to placebo in subjects with activeaxSpA Study to demonstrate the efficacy, safety and tolerability of an intravenous(i.v.) regimen of secuki ... | A randomized, double-blind, placebo-controlled, parallel group, phase IIImulticenter study of intravenous secukinumab to compare efficacy at 16weeks with placebo and to assess safety and tolerability up to 52 weeks insubjects with active Ankylosing Spondylitis or non-radiographic axialSpondyloArthritis A randomized, double-blind, placebo-controlled, parallel group, phase IIImulticenter study of intrav ... | Axial Spondyloarthritis MedDRA version: 21.1;Level: PT;Classification code 10071400;Term: Axial spondyloarthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Axial Spondyloarthritis MedDRA version: 21.1;Level: PT;Classification code 10071400;Term: Axial spon ... | Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: Secukinumab Other descriptive name: SECUKINUMAB Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: Secukinumab Other descriptive name: ... | Novartis Pharma AG | NULL | Not Recruiting | Female: yes Male: yes | 500 | Phase 3 | United States;Czechia;Philippines;Greece;Thailand;Guatemala;Turkey;Russian Federation;Colombia;Italy;India;Egypt;Czech Republic;Poland;Belgium;Brazil;Malaysia;Bulgaria;Sweden;Korea, Republic of United States;Czechia;Philippines;Greece;Thailand;Guatemala;Turkey;Russian Federation;Colombia;Italy ... | ||
| 8 | EUCTR2019-001177-90-BE (EUCTR) | 21/01/202020200121 | 22/10/201920191022 | Study to demonstrate the efficacy, safety and tolerability of an intravenous(i.v.) regimen of secukinumab compared to placebo in subjects with activeaxSpA Study to demonstrate the efficacy, safety and tolerability of an intravenous(i.v.) regimen of secuki ... | A randomized, double-blind, placebo-controlled, parallel group, phase IIImulticenter study of intravenous secukinumab to compare efficacy at 16weeks with placebo and to assess safety and tolerability up to 52 weeks insubjects with active Ankylosing Spondylitis or non-radiographic axialSpondyloArthritis A randomized, double-blind, placebo-controlled, parallel group, phase IIImulticenter study of intrav ... | Axial Spondyloarthritis MedDRA version: 21.1;Level: PT;Classification code 10071400;Term: Axial spondyloarthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Axial Spondyloarthritis MedDRA version: 21.1;Level: PT;Classification code 10071400;Term: Axial spon ... | Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: Secukinumab Other descriptive name: SECUKINUMAB Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: Secukinumab Other descriptive name: ... | Novartis Pharma AG | NULL | Not Recruiting | Female: yes Male: yes | 500 | Phase 3 | Thailand;Guatemala;Turkey;Russian Federation;Colombia;Italy;India;Egypt;Czech Republic;Poland;Belgium;Brazil;Malaysia;Bulgaria;Sweden;Korea, Republic of;United States;Czechia;Philippines;Greece Thailand;Guatemala;Turkey;Russian Federation;Colombia;Italy;India;Egypt;Czech Republic;Poland;Belgiu ... | ||
| 9 | EUCTR2017-000679-10-GR (EUCTR) | 05/03/201920190305 | 19/12/201820181219 | A randomized, partially-blinded, active-controlled multicenter study of secukinumab to demonstrate reduction of radiographic progression versus GP2017 (adalimumab biosimilar) at 104 weeks and to assess the long term safety, tolerability and efficacy up to 2 years in patients with active ankylosing spondylitis - SURPASS A randomized, partially-blinded, active-controlled multicenter study of secukinumab to demonstrate r ... | A randomized, partially-blinded, active-controlled multicenter study of secukinumab to demonstrate reduction of radiographic progression versus GP2017 (adalimumab biosimilar) at 104 weeks and to assess the long term safety, tolerability and efficacy up to 2 years in patients with active ankylosing spondylitis - SURPASS A randomized, partially-blinded, active-controlled multicenter study of secukinumab to demonstrate r ... | Ankylosing spondylitis MedDRA version: 20.0;Level: PT;Classification code 10002556;Term: Ankylosing spondylitis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Ankylosing spondylitis MedDRA version: 20.0;Level: PT;Classification code 10002556;Term: Ankylosing ... | Trade Name: COSENTYX INN or Proposed INN: secukinumab Other descriptive name: SECUKINUMAB Trade Name: Hyrimoz Product Name: adalimumab Product Code: GP2017 INN or Proposed INN: ADALIMUMAB Trade Name: COSENTYX INN or Proposed INN: secukinumab Other descriptive name: SECUKINUMAB Trade Name: H ... | Novartis Pharma AG | NULL | Not Recruiting | Female: yes Male: yes | 837 | Phase 3 | United States;Portugal;Philippines;Taiwan;Slovakia;Greece;Spain;Russian Federation;Israel;Chile;Colombia;France;Peru;Australia;Denmark;Netherlands;Korea, Republic of;Czechia;Finland;Turkey;Monaco;United Kingdom;Czech Republic;Mexico;Canada;Argentina;Belgium;Poland;Romania;Germany;Japan United States;Portugal;Philippines;Taiwan;Slovakia;Greece;Spain;Russian Federation;Israel;Chile;Colo ... | ||
| 10 | EUCTR2017-000679-10-SK (EUCTR) | 24/10/201820181024 | 02/10/201720171002 | Effect on secukinumab on radiographic progression in ankylosing spondylitis as compared to GP2017 (adalimumab biosimilar) Effect on secukinumab on radiographic progression in ankylosing spondylitis as compared to GP2017 (a ... | A randomized, partially-blinded, active-controlled multicenter study of secukinumab to demonstrate reduction of radiographic progression versus GP2017 (adalimumab biosimilar) at 104 weeks and to assess the long term safety, tolerability and efficacy up to 2 years in patients with active ankylosing spondylitis - SURPASS A randomized, partially-blinded, active-controlled multicenter study of secukinumab to demonstrate r ... | Ankylosing spondylitis MedDRA version: 20.0;Level: PT;Classification code 10002556;Term: Ankylosing spondylitis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Ankylosing spondylitis MedDRA version: 20.0;Level: PT;Classification code 10002556;Term: Ankylosing ... | Trade Name: COSENTYX INN or Proposed INN: secukinumab Other descriptive name: SECUKINUMAB Trade Name: Hyrimoz Product Name: adalimumab Product Code: GP2017 INN or Proposed INN: ADALIMUMAB Trade Name: COSENTYX INN or Proposed INN: secukinumab Other descriptive name: SECUKINUMAB Trade Name: H ... | Novartis Pharma AG | NULL | Not Recruiting | Female: yes Male: yes | 837 | Phase 3 | United States;Portugal;Philippines;Taiwan;Slovakia;Greece;Spain;Russian Federation;Israel;Chile;Colombia;France;Peru;Australia;Denmark;Netherlands;Korea, Republic of;Czechia;Finland;Turkey;Monaco;United Kingdom;Czech Republic;Mexico;Canada;Argentina;Belgium;Poland;Romania;Germany;Japan United States;Portugal;Philippines;Taiwan;Slovakia;Greece;Spain;Russian Federation;Israel;Chile;Colo ... |